Osteoarthritis, Knee Clinical Trial
Official title:
Optimizing the Body Mass Index: A Randomized Clinical Trial to Assess the Efficacy of Bariatric Surgery vs Medical Weight Loss in Morbidly Obese Patients Prior to Total Joint Arthroplasty
NCT number | NCT05156762 |
Other study ID # | H-41295 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | October 3, 2022 |
Est. completion date | November 2026 |
This is a randomized clinical trial (RCT) to assess the efficacy of bariatric surgery vs medical weight loss vs. the "usual standard of care" to optimize a morbidly obese patient with end-stage osteoarthritis of the hip or knee joint for total joint arthroplasty (TJA). The study population will include patients with hip or knee joint osteoarthritis and BMI (Body Mass Index) > 40 kg/m2 who are evaluated in the joint arthroplasty clinic at Boston Medical Center. The primary objective of the study is to determine if bariatric surgery or medical weight loss is more effective than the usual standard of care in optimizing a morbidly obese patient with osteoarthritis of the hip or knee joint for TJA. This will be determined by comparing the number of patients within each group who are able to lose weight through either bariatric surgery, medical weight loss, or the usual standard of care to achieve a BMI ≤ 40 kg/m2 to eventually undergo TJA. The secondary objectives of this study are to compare total operative time, postoperative complication rates, readmission rates, percentage of total body weight lost, revision rate, and reoperation rate. The ability of patients within each study arm to maintain a BMI ≤ 40 kg/m2 for up to 2 years after undergoing TJA will also be assessed, as well as their level of satisfaction before and after being in the study.
Status | Recruiting |
Enrollment | 138 |
Est. completion date | November 2026 |
Est. primary completion date | November 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria: - Patient must be 18 years or older who has met the clinical/standard care criteria for TJA (patient must have exhausted conservative measures to treat hip or knee joint arthritis (NSAIDS, physical therapy, corticosteroid injections)), except patient has a BMI > 40 kg/m2 - Patient must be interested in TJA as a treatment option - Patient must be willing to be randomized to either a bariatric surgery study arm, a medical weight loss study arm, or a "usual standard of care" study arm Exclusion Criteria: - Patient has undergone prior laparoscopic sleeve gastrectomy or gastric bypass - Patient has undergone prior hip or knee joint replacement for the affected joint - Active substance use disorder - Females with child-bearing potential |
Country | Name | City | State |
---|---|---|---|
United States | Boston Medical Center | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Boston Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bariatric surgery to achieve a BMI = 40 kg/m2 | The number of patients who are able to achieve a BMI = 40 kg/m2 prior to total joint arthroplasty (TJA) will be analyzed. | 12 months | |
Primary | Medical weight loss to achieve a BMI = 40 kg/m2 | The number of patients who are able to achieve a BMI = 40 kg/m2 prior to total joint arthroplasty (TJA) will be analyzed. | 12 months | |
Secondary | Percentage change in body weight | The percentage change in body weight lost will be calculated from baseline to TJA | Baseline, day of TJA | |
Secondary | Total TJA operative time | The total number of minutes will be abstracted from the operative report | Day of surgery | |
Secondary | Length of hospital stay for TJA procedure | The total number of days will be abstracted from the electronic health record (EHR). | Day of surgery until discharge from hospital, up to 7 days | |
Secondary | Surgical site infection rate | The proportion of participants who develop a postoperative surgical site infection | 90 days after TJA | |
Secondary | Venous thromboembolism rate | The proportion of participants who develop a postoperative deep venous thrombosis | 90 days after TJA | |
Secondary | Hematoma rate | The proportion of participants who develop a postoperative hematoma | 90 days after TJA | |
Secondary | Urinary tract infection rate | The proportion of participants who develop a postoperative urinary tract infection | 90 days after TJA | |
Secondary | Cardiac event rate | The proportion of participants who have a postoperative cardiac event | 90 days after TJA | |
Secondary | Prosthetic joint infection rate | The proportion of participants who have a postoperative prosthetic joint infection | 90 days after TJA | |
Secondary | 90 day postoperative readmission rate | The rate of hospital readmission 90 days after TJA | 90 days after TJA | |
Secondary | 24 month revision rate | Need for total hip or total knee arthroplasty component revision after primary total hip or total knee arthroplasty | 24 months | |
Secondary | 24 month reoperation rate | Need for reoperation for reasons other than component failure (surgical site infection, tendon injury) after primary total hip or total knee arthroplasty | 24 months | |
Secondary | Maintained a BMI = 40 kg/m2 post TJA | The number of participants who maintained a BMI = 40 kg/m2 for 24 months | 24 months post TJA | |
Secondary | Change in patient satisfaction with weight loss procedure | An investigator developed questionnaire will ask a question about how satisfied participants are with the weight loss procedure used from very satisfied to not at all satisfied. | Baseline, 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03895489 -
Effectiveness of the Journey Total Knee Arthroplasty Versus Two Standard of Care Total Knee Arthroplasty Prostheses
|
N/A | |
Completed |
NCT03660943 -
A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain
|
Phase 3 | |
Completed |
NCT04531969 -
Comparison of Outpatient and Inpatient Spa Therapy
|
N/A | |
Completed |
NCT02848027 -
Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment
|
Phase 3 | |
Completed |
NCT05160246 -
The Instant Effect of Kinesiology Taping in Patients With Knee OA
|
N/A | |
Recruiting |
NCT06080763 -
Biomechanics and Clinical Outcomes in Responders and Non-Responders
|
||
Completed |
NCT03643588 -
The Comparison of HYAJOINT Plus and Hyalgan Hyaluronan Supplement for Knee Osteoarthritis Pain
|
N/A | |
Active, not recruiting |
NCT05100225 -
Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis
|
Phase 2 | |
Active, not recruiting |
NCT04061733 -
New Hydroxyethyl Cellulose Hydrogel for the Treatment of the Pain of Knee Arthrosis
|
N/A | |
Completed |
NCT04051489 -
A Novel Smartphone Application for "Smart" Knee Osteoarthritis Trials
|
||
Recruiting |
NCT05546541 -
Epidemiology and Nutrition
|
||
Recruiting |
NCT05447767 -
Prediction AlgoriThm for regeneraTive Medicine Approach in knEe OA: New Decision-making Process Based on Patient pRofiliNg
|
Phase 2 | |
Not yet recruiting |
NCT04448106 -
Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis
|
Phase 2 | |
Not yet recruiting |
NCT03225911 -
Effect of a Lateral Wedge Insole and Simple Knee Sleeve in Individuals With Knee Osteoarthritis
|
N/A | |
Completed |
NCT05070871 -
A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women
|
N/A | |
Completed |
NCT05703087 -
Positive Cueing in Knee Arthroplasty.
|
N/A | |
Not yet recruiting |
NCT06042426 -
Effects of Perioperative Intravenous Dexamethasone in Clinical Outcomes After Total Knee Arthroplasty in a Hispanic Population
|
Phase 4 | |
Completed |
NCT03037489 -
A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients
|
Phase 2 | |
Not yet recruiting |
NCT02826850 -
Saphenous Nerve Radiofrequency for Knee Osteoarthritis Trial
|
Phase 3 | |
Not yet recruiting |
NCT02854176 -
Somatosensory Stimulation in Knee Osteoarthritis
|
Phase 2 |